Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Sten Peder Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing

doi:10.1186/1471-2369-11-29

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Sten Peder Andersen, Harald Mischak, Petra Zürbig, Hans-Henrik Parving, Peter Rossing

82 Citationer (Scopus)

Abstract

Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.

Originalsprog	Engelsk
Tidsskrift	B M C Nephrology
Vol/bind	11
Sider (fra-til)	29
ISSN	1471-2369
DOI	https://doi.org/10.1186/1471-2369-11-29
Status	Udgivet - 1 jan. 2010

Adgang til dokumentet

10.1186/1471-2369-11-29

Citationsformater

@article{33e37123d2df42fc8dac2d7448f2c7fe,

title = "Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria",

abstract = "Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.",

author = "Andersen, {Sten Peder} and Harald Mischak and Petra Z{\"u}rbig and Hans-Henrik Parving and Peter Rossing",

year = "2010",

month = jan,

day = "1",

doi = "10.1186/1471-2369-11-29",

language = "English",

volume = "11",

pages = "29",

journal = "B M C Nephrology",

issn = "1471-2369",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

AU - Andersen, Sten Peder

AU - Mischak, Harald

AU - Zürbig, Petra

AU - Parving, Hans-Henrik

AU - Rossing, Peter

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.

AB - Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.

U2 - 10.1186/1471-2369-11-29

DO - 10.1186/1471-2369-11-29

M3 - Journal article

C2 - 21040538

SN - 1471-2369

VL - 11

SP - 29

JO - B M C Nephrology

JF - B M C Nephrology

ER -

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater